1. in pregnancy, breast-feeding female patients, 2. to determine the history of chloroquine phosphate, rabeprazole drug allergy patients, Patients suffering from diseases of the blood system, 3. patients suffering from chronic liver and kidney diseases and reaching the terminal stage, 4. Serious heart, lung dysfunction and mental illness, 5. Patients with known retinal diseases, hearing loss or hearing loss, 6. Patients who have to take digitalis drugs for existing underlying diseases, 7. Merger of other digestive tract diseases, 8. Combine ribavirin, 9. Involved in other processing clinical drug trials.

1. in pregnancy, breast-feeding female patients, 2. to determine the history of chloroquine phosphate, rabeprazole drug allergy patients, Patients suffering from diseases of the blood system, 3. patients suffering from chronic liver and kidney diseases and reaching the terminal stage, 4. Serious heart, lung dysfunction and mental illness, 5. Patients with known retinal diseases, hearing loss or hearing loss, 6. Patients who have to take digitalis drugs for existing underlying diseases, 7. Merger of other digestive tract diseases, 8. Combine ribavirin, 9. Involved in other processing clinical drug trials.